JOHN NACKEL
General Partner at Wavemaker Three-Sixty Health
About
John Nackel is a General Partner at Wavemaker Three-Sixty Health, a leading venture capital firm focused on early-stage healthcare innovation. With a profound background in healthcare consulting and leadership, he spearheads investments in transformative digital health, medical device, and health technology companies. His expertise guides promising startups from seed to Series A funding, aiming to reshape the future of healthcare.
Experience
Deep Dive
John Nackel stands as a distinguished General Partner at Wavemaker Three-Sixty Health, a dedicated venture capital fund committed to fueling innovation in the healthcare sector. As a pivotal figure in the firm, John leverages his extensive industry knowledge and strategic acumen to identify and nurture promising early-stage healthcare technology companies. His role involves leading investment decisions, providing strategic guidance to portfolio companies, and fostering growth within the dynamic health tech landscape.
Wavemaker Three-Sixty Health, under John Nackel's leadership, primarily focuses on seed and Series A investments across a broad spectrum of healthcare verticals. These include cutting-edge digital health solutions, advanced medical devices, innovative diagnostics, health information technology, and tech-enabled healthcare services. John and his team seek out disruptive technologies and business models that have the potential to significantly improve patient outcomes, enhance operational efficiency, and reduce healthcare costs. Their investment thesis centers on backing visionary founders who are addressing critical challenges within the healthcare ecosystem.
John Nackel's career background is marked by a deep and enduring commitment to healthcare. Prior to his role at Wavemaker Three-Sixty Health, he held numerous leadership positions that provided him with an unparalleled understanding of the industry's complexities. He is widely recognized for his tenure as a national leader in healthcare consulting, notably as the former head of Ernst & Young's national healthcare practice. In this capacity, he advised countless healthcare organizations on strategy, operations, and technology adoption, gaining insights into both the challenges and opportunities within the sector. His operational experience also includes serving as CEO for various healthcare enterprises, further solidifying his expertise in scaling and managing healthcare businesses. This blend of consulting, operational, and investment experience makes him a uniquely qualified investor in the healthcare space.
While specific individual investments are part of Wavemaker Three-Sixty Health's portfolio, John Nackel's influence is evident in the firm's strategic direction and the types of companies it supports. The fund has a strong track record of investing in companies that are pioneering new approaches to chronic disease management, telehealth, AI-driven diagnostics, remote patient monitoring, and value-based care models. His guidance helps these startups navigate regulatory hurdles, market entry, and scaling challenges, positioning them for long-term success. John Nackel's dedication to fostering innovation ensures that Wavemaker Three-Sixty Health remains at the forefront of healthcare venture capital, driving meaningful advancements that benefit patients and providers alike.
Frequently Asked Questions
Who is John Nackel?
John Nackel is a General Partner at Wavemaker Three-Sixty Health, a venture capital firm specializing in early-stage healthcare technology investments. He is known for his extensive background in healthcare consulting and leadership.
What does John Nackel invest in?
John Nackel invests in early-stage healthcare technology companies, including digital health, medical devices, diagnostics, health information technology, and tech-enabled healthcare services, primarily at the seed and Series A stages.
Where does John Nackel work?
John Nackel works as a General Partner at Wavemaker Three-Sixty Health, a dedicated healthcare venture capital fund.